- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00880750
Pharmacodynamic Study of Two Lanthanum Carbonate Formulations in Healthy Adults
June 4, 2021 updated by: Shire
A Phase I Pharmacodynamic Equivalence Study Comparing Urinary Phosphate Excretion and Plasma Lanthanum Pharmacokinetics for a Lanthanum Carbonate Granule Formulation and Chewable Tablets Administered to Healthy Adult Subjects
This study is being conducted to assess any potential differences in the absorption and excretion between two lanthanum carbonate formulations.
This study is also being done to assess the safety and tolerability of the two lanthanum carbonate formulations.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
72
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Cypress, California, United States, 90630
- West Coast Clinical Trials, Llc
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
- Ability to provide informed consent to participate in the study.
- Healthy volunteers, age 18-55 inclusive.
- Subject must be willing to comply with applicable contraceptive requirements of the protocol
- Female subjects must have a negative pregnancy test
- Ability to chew and or swallow doses of the investigational products as prescribed in the protocol.
- Ability to fully comply with all study procedures and restrictions, including consumption of all food provided while a resident in the CRC.
Exclusion Criteria
- Current or relevant previous history of physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully complete the study, or any condition that presents undue risk from the investigational product or study procedures.
- Clinically significant abnormal serum phosphate levels, outside of normal limits.
- Current use of any medication with the exception of hormonal replacement therapy or hormonal contraceptives within 7 days of first dose of investigational product.
- A known history of lactose intolerance or allergy to milk or other foods.
- Clinically significant or multiple allergies as determined by an Investigator.
- History of alcohol or other substance abuse within the last 6 months.
- A positive screen for alcohol or drugs of abuse.
- Male subjects who consume more than 21 units of alcohol per week or three units per day. Female subjects who consume more than 14 units of alcohol per week or two units per day.
- A positive human immunodeficiency virus (HIV) antibody screen, Hepatitis B surface antigen (HBsAg) or Hepatitis C virus (HCV) antibody screen.
- Female subjects who are pregnant (positive pregnancy test), lactating, or less than 90 days post-partum.
- Subjects that have previously been randomized in this study.
- Use of tobacco in any form or other nicotine-containing products in any form. Ex-users must report that they have stopped using tobacco for at least 60 days prior to receiving the first dose of investigational product.
- Routine consumption of more than two units of caffeine per day or subjects who experience caffeine withdrawal headaches.
- Donation of blood or blood products within 60 days prior to receiving the first dose of investigational product.
- Plasma donation within 28 days prior to the first dose of the investigational product.
- Use of another investigational product within 30 days prior to receiving the first dose of investigational product or active enrolment in another drug or vaccine clinical study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lanthanum carbonate granules
Lanthanum carbonate granulated formulation crossover to chewable tablet formulation
|
3x's per day for 3 days, 1 dose in the am for day 4. (A single dose equals 1000mg of lanthanum carbonate granule formulation.
Dose is administered immediately after each meal.)
|
Experimental: Lanthanum carbonate chewable tablets (Fosrenol)
Lanthanum carbonate chewable table formulation crossover to granulated formulation
|
3x's per day for 3 days, 1 dose on day 4. (A single dose equals a 1000mg tablet of lanthanum carbonate.
Dose is administered immediately after each meal.)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Urinary Phosphate Excretion 3-Day Average
Time Frame: Continuous collection over 3 days
|
Continuous collection over 3 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Urinary Phosphate Excretion on Day 4
Time Frame: Continuous collection on Day 4
|
Continuous collection on Day 4
|
Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Lanthanum Carbonate
Time Frame: 3, 4, 5, 6, 8, 12, 18, 24, 36 and 48 hours post-dose on Day 4
|
3, 4, 5, 6, 8, 12, 18, 24, 36 and 48 hours post-dose on Day 4
|
Maximum Plasma Concentration (Cmax) of Lanthanum Carbonate
Time Frame: 3, 4, 5, 6, 8, 12, 18, 24, 36 and 48 hours post-dose on Day 4
|
3, 4, 5, 6, 8, 12, 18, 24, 36 and 48 hours post-dose on Day 4
|
Time of Maximum Plasma Concentration (Tmax) of Lanthanum Carbonate
Time Frame: 3, 4, 5, 6, 8, 12, 18, 24, 36 and 48 hours post-dose on Day 4
|
3, 4, 5, 6, 8, 12, 18, 24, 36 and 48 hours post-dose on Day 4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 28, 2009
Primary Completion (Actual)
June 22, 2009
Study Completion (Actual)
June 22, 2009
Study Registration Dates
First Submitted
April 13, 2009
First Submitted That Met QC Criteria
April 13, 2009
First Posted (Estimate)
April 14, 2009
Study Record Updates
Last Update Posted (Actual)
June 11, 2021
Last Update Submitted That Met QC Criteria
June 4, 2021
Last Verified
June 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SPD405-127
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End Stage Renal Disease
-
Outset MedicalCompletedAcute Kidney Injury | End Stage Renal Disease (ESRD) | End Stage Renal Disease on DialysisUnited States
-
University of Illinois at ChicagoWithdrawnObesity | End-Stage Renal Disease | Renal Disease, End-Stage | Renal Failure, End-StageUnited States
-
Bioconnect Systems, IncCompletedEnd-stage Renal Disease | End-stage Kidney DiseaseUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...Changhai Hospital; Shanghai Zhongshan Hospital; RenJi Hospital; Ruijin Hospital; Shanghai... and other collaboratorsCompleted
-
Clinical Research Center for End Stage Renal Disease...Kyungpook National University Hospital; Medical Research Collaborating Center... and other collaboratorsActive, not recruitingEnd-Stage Renal DiseaseKorea, Republic of
-
Medtronic - MITGCompletedEnd-stage Renal DiseaseGermany
-
China Medical University HospitalUnknown
-
Guangdong Provincial Hospital of Traditional Chinese...Ministry of Science and Technology of the People´s Republic of ChinaUnknown
-
University of California, San FranciscoCompletedEnd-stage Renal DiseaseUnited States
-
Mark A. LumleyHenry Ford Health SystemCompleted
Clinical Trials on Lanthanum carbonate Granule Formulation
-
University of Illinois at ChicagoShireCompletedHyperphosphatemia | Kidney DiseaseUnited States
-
University of Wisconsin, MadisonShireCompleted
-
ShireCompleted
-
ShireCompleted
-
ShireCompletedHyperphosphatemiaUnited States, Germany, United Kingdom
-
Universitair Ziekenhuis BrusselRecruitingNephrolithiasis | Secondary HyperoxaluriaBelgium
-
ShireCompleted
-
BayerCompleted